Citations

Clear

12 citation(s) found for "Liu, Hui".

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2
Harding, James J. , Oh, Do‐Youn , Macarulla, Teresa , Goyal, Lipika , Varkaris, Andreas , Palmieri, Lola‐Jade , Ikeda, Masafumi , Kondo, Shunsuke , Bai, Li‐Yuan , Ueno, Makoto , Papadopoulos, Kyriakos P. , Shroff, Rachna T. , Kizilbash, Sani H. , Liao, Chih‐Yi , Azad, Nilofer S. , Jaeckle, Kurt A. , Bender, Mark H. , Varughese, Sunoj Chacko , Sachdeva, Deepa , Radtke, David B. , Gueorguieva, Ivelina , Chen, Hsiao-Rong , Liu, Hui , Xu, Xiangyuan , Macarulla, Teresa , Chen, Li-Tzong , Papadopoulos, Kyriakos P , Shroff, Rachna T , Kizilbash, Sani H , Hollebecque, Antoine , Adeva, Jorge , Cosman, Rasha , Yokota, Tomoya , Park, Joon Oh , Turk, Anita , Liao, Chih-Yi , Satoh, Taroh , Borad, Mitesh J , El-Khouiery, Anthony B , Azad, Nilofer , Jaeckle, Kurt A , Loong, Herbert H , Yong, Wei-Peng , Bender, Mark H , Varughese, Sunoj Chacko , Sachdeva, Deepa , Radtke, David B , Gueorguieva, Ivelina , Szpurka, Anna M , Chen, Hsiao-Rong , Liu, Hui , Xu, Xiaojian , Rodon, Jordi , Ikeda, Masafumi , Goyal, Lipika , Harding, James J , Chen, Li‐Tzong , Adeva, Jorge , Yokota, Tomoya , Borad, Mitesh J. , El-Khoueiry, Anthony B. , Loong, Herbert H. , Yong, Wei Peng

Mayo Clinic

Clinical Cancer Research | September 30, 2025 | Volume: 31 | Issue: 23 | Pages: 4920-4932

10.1158/1078-0432.ccr-25-0174 | PMID 41026608 Get It

Abstract Purpose: Isocitrate dehydrogenase (IDH) 1/2–isoform inhibitors have clinical efficacy in IDH1/IDH2-mutated neoplasms. However, primary resistance and secondary resistance limit their therapeutic potential. LY3410738, an oral, brain-penetrant, dual IDH1/IDH2-mutated isoform-selective inhibitor, was designed to overcome resistance. Patients and Methods: This global, multicenter, open-label, phase I study of patients with IDH-mutant solid tumors evaluated LY3410738 as monotherapy (dose escalation) for advanced solid tumors in combination with cisplatin–gemcitabine (CISGEM) for newly diagnosed cholangiocarcinoma or with durvalumab for relapsed/refractory cholangiocarcinoma (dose expansion; NCT04521686). Primary objectives were the maximum tolerated dose, recommended phase II dose, and preliminary antitumor activity. Safety, pharmacokinetics, inhibition of D-2-hydroxyglutarate, and ctDNA were assessed. Results: Overall, 119 patients received LY3410738 alone (N = 94) or in combination with CISGEM (N = 19) or durvalumab (N = 6). No dose-limiting toxicities were observed; the maximum tolerated dose was not determined. Common adverse events included nausea, vomiting, and decreased appetite. Overall response rates of 5.2% and 11.1% and disease control rates of 56.9% and 63.0% were observed for patients with relapsed/refractory IDH1- or IDH2-mutant cholangiocarcinoma or IDH1-mutant glioma, respectively. D-2-hydroxyglutarate normalization was rapid and durable. In dose-expansion cohorts, combination treatments were tolerable, with one dose-limiting toxicity in the durvalumab cohort. LY3410738 plus CISGEM demonstrated a response rate of 42.1%, a median duration of response of 8.1 months, and a median progression-free survival of 10.2 months for patients with newly diagnosed IDH-mutant cholangiocarcinoma. Conclusions: LY3410738 demonstrated largely cytostatic antitumor activity in IDH1- or IDH2-mutated cholangiocarcinoma and IDH1-mutated gliomas. LY3410738 plus CISGEM exhibited favorable antitumor activity in patients with treatment-naïve IDH-mutated cholangiocarcinoma, warranting further exploration as a treatment strategy.
Outcome of Goniotomy Over 120, 240 and 360 Degrees in Juvenile Open Angle Glaucoma: A Multicenter Study
Wang, Zhixuan , Fan, Hanying, Ge, Qingshu, Dang, Guangfu , Yang, Xiao , Xie, Lin , Zhu, Xiaoming , Yang, Yangfan , Wang, Yuhong , Liu, Jinkun , Zhang, Hongyang , Feng, Yuhan, Qi, Yongjun , Ye, Xiangxiang, Lai, Mingying , Lin, Peijie , Wang, Pusheng, Han, Shumei, Xu, Jiangang , Tao, Liming, Liu, Heting , Nie, Xin , Liao, Mengfei, Zou, Kai , Song, Yunhe , Lin, Fengbin , Xiaokaiti, Dilimulati, Liu, Xiaoyi , Fang, Zige , Jin, Ling, Chen, Yu , Han, Ying , Zeng, Liuzhi , Tham, Clement C, Yang, Zefeng , Ye, Xiangxiang, Lin, Peijie , Wang, Pusheng, Han, Shumei, Nie, Xin, Zou, Kai, Jiang, Yi , Zhou, Fengqi , Tham, Clement Chee Yung , Pan, Xiaojing , Weinreb, Robert Neal , Zhang, Xiulan

Mayo Clinic

Journal of Glaucoma | March 19, 2025 | Volume: 34 | Issue: 6 | Pages: 433-439

10.1097/ijg.0000000000002569 | PMID 40105411 Get It

Précis: 240-degree and 360-degree goniotomy (GT) demonstrated similar efficacy in intraocular pressure (IOP) reduction, both outperforming 120-degree GT in patients with juvenile open angle glaucoma (JOAG) at postoperative 6-month follow-up. Objective: To compare the surgical efficacy and safety of 120-degree, 240-degree, and 360-degree GT for patients with JOAG. Patients and Methods: This multicenter retrospective study included 102 eyes of 102 patients with JOAG, who underwent GT with a follow-up of at least 6 months. Patients were categorized into 3 groups: (1) 120-degree GT, (2) 240-degree GT, and (3) 360-degree GT. IOP, glaucoma medications, and complications were recorded at baseline and the final visit. Complete success and qualified success were defined as a postoperative IOP ≤21 mm Hg without and with medications, respectively. Results: Mean age of the participants was 24.4 ± 7.9 years. After a mean follow-up of 8.1 ± 2.7 months, complete success rates were similar between the 240-degree GT (45.2%) and the 360-degree GT (63.2%; P = 0.135), and both were superior to 120-degree GT (18.2%; P < 0.05). Qualified success rates among patients in the 120-degree, 240-degree, and 360-degree GT groups were 93.9%, 96.8%, and 100%, respectively, and showed no statistically significant difference (P = 0.292). 360-degree GT required fewer medications than 240-degree GT and 120-degree GT (P < 0.05), with no significant difference in medications between 120-degree GT and 240-degree GT (P > 0.05). Hyphema was the most common postoperative complication, with a significantly higher incidence in the 360-degree GT (68.4%) compared with the 240-degree GT (41.9%) and 120-degree GT (33.3%; P < 0.05). Conclusions: 240-degree and 360-degree GT showed similar efficacy in IOP reduction and were superior to 120-degree GT. More extensive GT may provide better outcomes in JOAG.
Pig-to-human lung xenotransplantation in a brain-dead human recipient
Liu, Xiaoyou , Peng, Guilin, Shi, Jiang , Ju, Chunrong, He, Ping , Liu, Xiaoqing , Zhang, Zuopen, Chen, Chuanbao, Pan, Dengke, Yang, Zifeng , Guan, Wenda, 陈, 中华克劳斯, Liu, Menyang, Liang, Hengrui , Zhao, Yi , Huang, Weiqing , Rucker, A. Justin , Xu, Xin , He, Jianxing , Yang, Chao , Liu, Hui, Liu, Xiaoqing, Zhang, Zuopeng , Pan, Dengke , Yang, Zifeng , Guang, Wenda, Li, Hongtao , Chen, Zhonghua, Liang, Hengrui , Jeon, Kyeongman , Chen-Yoshikawa, Toyofumi Fengshi , Lal, Amos, Zhang, Kang , Zhang, Kang , Liu, Xiaoyou , Xu, Xin

Mayo Clinic

No container title available | November 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5155123/v1 Get It

Abstract This study reports the first pig-to-human lung xenotransplantation using a six gene-edited pig lung. A left lung from a gene-edited Chinese Bama Xiang pig was transplanted into a 39-year-old brain-dead human recipient. The xenograft maintained viability and functionality for 216 hours without signs of hyperacute rejection. Postoperatively, severe edema resembling primary graft dysfunction (PGD) was observed, potentially due to ischemia-reperfusion injury. Antibody-mediated rejection appeared to contribute to xenograft damage on postoperative days 3 and 6, with partial recovery by day 9 under the current immunosuppressive regimen. This pioneering study suggests that genetically modified pig lungs could potentially be used for future clinical applications in xenotransplantation.
Novel Quantitative Liver Steatosis Assessment Method With Ultrasound Harmonic Imaging
Zhang, Jingke , Huang, Chengwu , Tang, Shanshan , Liu, Hui , DeRuiter, Ryan M. , Petersen, Kendra E , Knoll, Kate M , Robinson, Kathryn, Watt, Kymberly D., Callstrom, Matthew R. , Chen, Shigao , Petersen, Kendra E. , Zhang, Jingke , Lok, U-Wai , Liu, Hui , DeRuiter, Ryan , Petersen, Kendra, Knoll, Kate, Watt, Kymberly, Callstrom, Matthew, Huang, Chengwu , Gong, Ping , Lok, U‐Wai , Robinson, Kathryn

Mayo Clinic

Journal of Ultrasound in Medicine | September 24, 2024 | Volume: 44 | Issue: 1 | Pages: 77-85

10.1002/jum.16582 | PMID 39315751 Get It

ObjectivesMetabolic dysfunction‐associated steatotic liver disease (MASLD) is the most prevalent liver disorder in Western countries, with approximately 20%–30% of the MASLD patients progressing to severe stages. There is an urgent need for noninvasive, cost‐effective, widely accessible, and precise biomarkers to evaluate liver steatosis. This study aims to assess and compare the diagnostic performance of a novel reference frequency method‐based ultrasound attenuation coefficient estimation (ACE) in both fundamental (RFM‐ACE‐FI) and harmonic (RFM‐ACE‐HI) imaging for detecting and grading liver steatosis.MethodsAn Institutional Review Board‐approved prospective study was carried out between December 2018 and October 2022. A total number of 130 subjects were enrolled in the study. The correlation between RFM‐ACE‐HI values and magnetic resonance imaging proton density fat fraction (MRI‐PDFF), as well as between RFM‐ACE‐FI values and MRI‐PDFF were calculated. The diagnostic performance of RFM‐ACE‐FI and RFM‐ACE‐HI was evaluated using receiver operating characteristic (ROC) curve analysis, as compared to MRI‐PDFF. The reproducibility of RFM‐ACE‐HI was assessed by interobserver agreement between two sonographers.ResultsA strong correlation was observed between RFM‐ACE‐HI and MRI‐PDFF, with R = 0.88 (95% confidence interval [CI]: 0.83–0.92; P < .001), while the correlation between RFM‐ACE‐FI and MRI‐PDFF was R = 0.65 (95% CI: 0.50–0.76; P < .001). The area under the ROC (AUROC) curve for RFM‐ACE‐HI in staging liver steatosis grades of S ≥ 1 and S ≥ 2 was 0.97 (95% CI: 0.91–0.99; P < .001) and 0.98 (95% CI: 0.93–1.00; P < .001), respectively, and 0.76 (95% CI: 0.65–0.85) and 0.80 (95% CI: 0.70–0.88) for RFM‐ACE‐FI, respectively. Great reproducibility was achieved for RFM‐ACE‐HI, with an interobserver agreement of R = 0.97 (95% CI: 0.94–0.99; P < .001).ConclusionsThe novel RFM‐ACE‐HI method offered high liver steatosis diagnostic accuracy and reproducibility, which has important clinical implications for early disease intervention and treatment evaluation.
Enhancing Row-Column Array (RCA)-Based 3D Ultrasound Vascular Imaging With Spatial-Temporal Similarity Weighting
Zhang, Jingke , Huang, Chengwu , Dong, Zhijie , Liu, Hui , Song, Pengfei , Chen, Shigao , Song, Pengfei , Huang, Chengwu , Zhang, Jingke , Liu, Hui , Lok, U‐Wai , Gong, Ping

Mayo Clinic

IEEE Transactions on Medical Imaging | August 6, 2024 | Volume: 44 | Issue: 1 | Pages: 297-309

10.1109/tmi.2024.3439615 | PMID 39106128 Get It

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study
Shah, Nirav N. , Lewis, David , Coombs, Catherine C. , Lamanna, Nicole , Jagadeesh, Deepa, Munir, Talha, Eyre, Toby A. , McKinney, Matthew , Alencar, Alvaro J. , Seymour, John F. , Woyach, Jennifer A. , Abada, Paolo, Ho, Caleb , Marella, Narasimha, Wang, Chunxiao , Ruppert, Amy S. , Nair, Binoj C., Liu, Hui , Tsai, Donald E. , Wierda, William G. , Cheah, Chan Y. , Hoffmann, Marc Steven , Ma, Shuo , Jagadeesh, Deepa , Wang, Yucai , Rhodes, Joanna , Lech‐Marańda, Ewa , Tam, Constantine S. , Jurczak, Wojciech , Izutsu, Koji , Patel, Manish R. , Roeker, Lindsey E. , Thompson, Philip A , Ghia, Paolo

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 1737-1737

10.1182/blood-2023-181108 Get It

Background:Richter transformation (RT) occurs in up to 10% of patients with chronic lymphocytic leukemia (CLL), typically presents as an aggressive diffuse large B-cell lymphoma (DLBCL) and is associated with poor survival. RT has no approved standard therapy; and clinical trial enrollment is the preferred first line of therapy. Pirtobrutinib, a highly selective, non-covalent (reversible) BTKi, that inhibits both wildtype and C481-mutant BTK with equal low nM potency, has favorable oral pharmacology that enables continuous BTK inhibition throughout the dosing interval. Pirtobrutinib demonstrated durable overall response rates (ORR) and was well tolerated in patients (pts) with poor-prognosis B-cell malignancies regardless of prior therapy. Here we provide updated safety and efficacy of pirtobrutinib in RT pts from the phase 1/2 BRUIN trial (NCT03740529). Methods: Pts with previously treated, histologically confirmed RT were eligible in the global, multicenter, phase 1/2 BRUIN study. Pts with untreated RT became eligible after Amendment 10. All but one patient received the recommended phase 2 dose of 200 mg daily. Key endpoints included investigator-assessed ORR, DoR per Lugano 2014 criteria, OS, and safety. A data cut of 05 May 2023 was utilized. To assess clonal relationship, IGH rearrangement studies were done on tissue biopsies with RT involvement, and baseline blood or bone marrow (BM) samples with CLL involvement. Results: Among all pts with RT (N=82) the median age was 67 (range, 26-95) and the median total number of lines of prior systemic therapy was 4 (range, 0-13). Pts with prior treatment had a median of 2 CLL-directed therapies and 2 RT-directed therapies. Eight pts did not have a previous line of RT-directed therapy, and 1 patient received neither RT- nor CLL-directed therapy. Common prior RT- and CLL-directed therapies (RT, CLL) included: chemotherapy (76%, 52%), cBTKi (34%, 62%), anti-CD20 antibody (78%, 66%), BCL2i (38%, 49%), stem cell transplant (SCT; 6%, 7%), and CAR-T (11%, 4%). Of 29 pts with bone marrow screening, 41.4% had CLL alone present in BM, 13.8% had DLBCL present and 24.1% had both CLL and DLBCL present. For 39 pts with available PET data, the median SUVmax was 19.1 (range, 2.6-41.2). For all 82 pts, the ORR was 50.0% (95% CI, 38.7-61.3) including complete (13.4%, n=11) and partial (36.6%, n=30) responses. For 61 pts who received prior cBTKi therapy, the ORR was 45.9% (95% CI 33.1-59.2). Among 28 pts with an RT-directed cBTKi and 51 pts with prior CLL-directed cBTKi, the ORR was 42.9% (95% CI, 24.5-62.8) and 43.1% (95% CI, 29.3-57.8), respectively. In 50 pts who discontinued prior cBTKi due to disease progression, the ORR was 42.0% (95% CI, 28.2-56.8). At median follow-up time of 9.7 months, the median DoR for all 82 RT pts was 7.4 months (95% CI, 3.1-19.1) and the estimated rate at 12 months was 45.9% (95% CI, 28.3-61.8). The median time on treatment for the 41pts who responded to treatment was 8.3 months. Eight pts stopped pirtobrutinib to pursue curative-intent allogeneic SCT and DoR was censored at the last preceding disease assessment. At a median survival follow-up of 18.3 months, the median OS for the entire RT cohort was 12.5 months (95% CI, 6.9-20.5). At 18 months, the OS rate was 44.3% (95% CI, 32.5-55.4). Frequent treatment-emergent adverse events (TEAE) in the RT cohort (n=82) were neutropenia/decreased neutrophil count (29.3%, n=24), fatigue (24.4%, n=20) and diarrhea, dyspnea, thrombocytopenia, and pyrexia (18.3% each, n=15). Common grade ≥3 TEAEs were neutropenia/decreased neutrophil count (23.2%, n=19), thrombocytopenia (11.0%, n=9), plus anemia and sepsis (9.8% each, n=8). Any grade hypertension (3.7%, n=3) or atrial fibrillation (1.2%, n=1) were infrequent. Three pts (3.7%) had treatment-related AEs leading to dose reductions, but no pt had a treatment-related AE leading to pirtobrutinib discontinuation. Analyses of clonality will be presented. Conclusions: Continued follow-up from BRUIN demonstrates encouraging response and OS in pts with RT. Pirtobrutinib remains well-tolerated with low rates of discontinuation and manageable safety profile. While RT remains a challenging diagnosis, pirtobrutinib represents a potential treatment option that warrants further investigation.
Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors
Mercadé, T. Macarulla, Oh, Do‐Youn , Bai, Li‐Yuan , Ueno, Makoto, Papadopoulos, Kyriakos P. , Kizilbash, Sani H. , Yokota, Tomoya , Liao, Chih‐Yi , Shroff, Rachna T. , Satoh, Taroh, Azad, Nilofer S. , Jaeckle, Kurt A. , Zhao, Junjie , Gueorguieva, Ivelina , Pradhan, Kamnesh R. , Kizilbash, Sani H , Yokota, Tomoya , Rodon, Jordi , Goyal, Lipika , Ikeda, Masafumi , Kondo, Shunsuke , Ueno, Makoto , Italiano, Antoîne , Spigel, David R. , Cosman, Rasha , Park, Joon Oh , Chen, Li‐Tzong , Turk, Anita , El-Khoueiry, Anthony B. , Hollebecque, Antoine , Borad, Mitesh J. , Loong, Herbert H. , Adeva, Jorge , Yong, Wei Peng , Liu, Hui , Szpurka, Anna M , Xu, Xiaojian , Harding, James J.

Mayo Clinic

Cancer Research | April 14, 2023 | Volume: 83 | Issue: 8_Supplement | Pages: CT098-CT098

10.1158/1538-7445.am2023-ct098 Get It

Abstract Background: Isocitrate dehydrogenase 1/2 (IDH1/2) is mutated in a subset of cholangiocarcinoma (CCA), gliomas, and other solid tumors. LY3410738 is a potent, selective, covalent, dual inhibitor of IDH1/2 mutations (IDH1/2m). LY3410738 binds covalently at a novel binding site, enabling continued potency in preclinical models in the setting of second site IDH resistance mutations. We present initial results from the first-in-human phase 1 study of oral LY3410738 in patients (pts) with IDH1/2m CCA, and IDH1m glioma or other solid tumors. Methods: Dose escalation (3+3 design) evaluated LY3410738 monotherapy in advanced IDHm CCA and other solid tumors (NCT04521686). Key objectives included determining the RP2D, safety, PK, PD (inhibition of plasma D-2-HG), and preliminary antitumor activity. Results: As of 28 July 2022, 80 pts including 42 with CCA (33 IDH1m, 9 IDH2m), 27 with glioma (IDH1m), and 11 other tumor types (IDH1m) received LY3410738 dosed at 25-600 mg QD or 300 mg BID. Pts were median 52 years of age (range, 23-80) with a median of 2 prior therapies (range, 1-7). 19% of CCA pts had received prior IDH1 inhibitor. Median time on treatment was 3.7 months (range, 0.1-19). No DLTs or treatment related deaths were observed; the MTD was not reached. Treatment emergent adverse events (TEAEs) ≥15% included nausea (35%), vomiting (21%), and decreased appetite (19%) and were mostly grade 1-2. Most frequent grade ≥3 TEAEs &gt;2% were anemia (4%), cholangitis (3%), headache (3%), decreased lymphocyte count (3%), and hyponatremia (3%). LY3410738 exposure was dose proportional. In pts with IDH1m cancers, LY3410738 achieved sustained D-2-HG inhibition at all dose levels, including in pts who received prior IDH1 inhibitor. In pts with IDH2m cancers, a higher dose (≥150 mg daily dose) was required for D-2-HG inhibition. Among the 42 pts with R/R CCA, the best response included 1 PR and 22 SD. Of the 22 glioma pts with contrast enhancing tumors, best response included 3 PR and 9 SD. Conclusions: LY3410738 demonstrated a favorable safety profile with potent and sustained D-2-HG inhibition in pts with IDH1/2m advanced solid tumors. Consistent with the expectations for IDH inhibitor monotherapy in this setting, CCA and glioma pts exhibited prolonged stable disease. RP2D evaluation is ongoing. Updated data on LY3410738 monotherapy will be presented at the meeting. Citation Format: Jordi Rodon, Lipika Goyal, Teresa Macarulla Mercade, Masafumi Ikeda, Shunsuke Kondo, Do-Youn Oh, Li-Yuan Bai, Makoto Ueno, Antoine Italiano, Kyriakos Papadopoulos, David Spigel, Sani H. Kizilbash, Rasha Cosman, Joon Oh Park, Li-Tzong Chen, Tomoya Yokota, Anita A. Turk, Chih-Yi Liao, Rachna Shroff, Anthony El-Khoueiry, Taroh Satoh, Antoine Hollebecque, Mitesh J. Borad, Nilofer Azad, Kurt A. Jaeckle, Herbert H. Loong, Jorge Adeva, Wei Peng Yong, Junjie Zhao, Hui Liu, Anna M. Szpurka, Ivelina Gueorguieva, Kamnesh R. Pradhan, Xiaojian Xu, James J. Harding. A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT098.
EBV+ high‐grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi‐institutional study
Liu, Hui , Wang, Wei , Kim, Young , Ji, Yuan , Chen, Weina , Fedoriw, George Y, Zhu, Feng , Luedke, Catherine, Hu, Shimin , Hu, Shimin , Yuan, Ji , Xu‐Monette, Zijun Y. , Tang, Guilin , Li, Yu , Li, Yanping , Fang, Xiaosheng , Medeiros, L. Jeffrey , Young, Ken H.

Mayo Clinic

Histopathology | October 13, 2021 | Volume: 80 | Issue: 3 | Pages: 575-588

10.1111/his.14585 | PMID 34637146 Get It

AimsIt is unknown whether Epstein–Barr virus (EBV) infection can occur in high‐grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, also known as double‐ or triple‐hit lymphoma (DHL/THL).Methods and resultsHere we report 16 cases of EBV+ DHL/THL from screening 846 cases of DHL/THL and obtaining additional EBV+ cases through multi‐institutional collaboration: eight MYC and BCL2 DHL, six MYC and BCL6 DHL and two THL. There were eight men and eight women, with a median age of 65 years (range = 32–86). Two patients had a history of follicular lymphoma and one had AIDS. Nine of 14 patients had an International Prognostic Index of ≥3. Half of the cases showed high‐grade/Burkitt‐like morphology and the other half diffuse large B cell lymphoma morphology. Using immunohistochemistry, the lymphoma cells were positive for MYC (n = 14 of 16), BCL2 (n = 12 of 16), BCL6 (n = 14 of 16), CD10 (n = 13 of 16) and MUM1 (n = six of 14). Using Hans’ algorithm, 13 cases were classified as germinal centre B cell (GCB) and three as non‐GCB. The lymphomas frequently showed an EBV latency Type I with a median EBV‐encoded small RNAs of 80% positive cells (range = 20–100%). After a median follow‐up of 36.3 months (range = 2.0–41.6), seven patients died, with a median survival of 15.4 months (range = 3.4–47.3) after diagnosis of EBV+ DHL/THL. Five of six patients with MYC and BCL6 DHL were alive, including four in complete remission. In contrast, only four of 10 patients with MYC and BCL2 DHL or THL were alive, including two in complete remission. The median survival in patients with MYC and BCL6 DHL was unreached and was 21.6 months in patients with MYC and BCL2 DHL or THL.ConclusionsEBV infection in DHL/THL is rare (~1.5%). Cases of EBV+ DHL/THL are largely similar to their EBV– counterparts clinicopathologically. Our findings expand the spectrum of EBV+ B cell lymphomas currently recognised in the World Health Organisation classification and suggest differences between EBV+ MYC and BCL2 DHL versus EBV+MYC and BCL6 DHL that may have therapeutic implications.
TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells
Barbosa, Mayara Garcia de Mattos , Lefferts, Adam R. , Huynh, Daniel , Liu, Hui , Zhang, Yu , Barnes, Jenna , Samaniego, Milagros , Bram, Richard J. , Geha, Raif , Shikanov, Ariella , Farkash, Evan A. , Platt, Jeffrey L. , Samaniego-Picota, Milagros , Fu, Beverly, Geha, Raif , Prak, Eline T. Luning , Cascalho, Marília

Mayo Clinic

JCI Insight | July 20, 2021 | Volume: 6 | Issue: 17 | Pages: No page available

10.1172/jci.insight.150483 | PMID 34283811 Get It

Host genes define the severity of inflammation and immunity but specific loci doing so are unknown. Here we show that TNF receptor superfamily member 13B ( TNFRSF13B ) variants, which enhance defense against certain pathogens, also control immune-mediated injury of transplants, by regulating innate B cells’ functions. Analysis of TNFRSF13B in human kidney transplant recipients revealed that 33% of those with antibody-mediated rejection (AMR) but fewer than 6% of those with stable graft function had TNFRSF13B missense mutations. To explore mechanisms underlying aggressive immune responses, we investigated alloimmunity and rejection in mice. Cardiac allografts in Tnfrsf13b- mutant mice underwent early and severe AMR. The dominance and precocity of AMR in Tnfrsf13b -deficient mice were not caused by increased alloantibodies. Rather, Tnfrsf13b mutations decreased “natural” IgM and compromised complement regulation, leading to complement deposition in allografted hearts and autogenous kidneys. Thus, WT TNFRSF13B and Tnfrsf13b support innate B cell functions that limit complement-associated inflammation; in contrast, common variants of these genes intensify inflammatory responses that help clear microbial infections but allow inadvertent tissue injury to ensue. The wide variation in inflammatory reactions associated with TNFRSF13B diversity suggests polymorphisms could underlie variation in host defense and explosive inflammatory responses that sometimes enhance morbidity associated with immune responses.
Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma
Ferrufino‐Schmidt, María C. , Medeiros, L. Jeffrey , Liu, Hui , Clemens, Mark W. , Laurent, Camille , Lofts, Julian , Amin, Mitual , Chai, Siaw Ming , Morine, Angela, Napoli, Arianna Di , Bhagat, Govind , Tritz, Denise, Quesada, Andres , Hu, Qinlong, Gómez, Francisco Javier García , Martín, Juan José Borrero , Thakral, Beenu , Narbaitz, Marina, Hughes, R. Condon, Yang, Li-Jun, Fromm, Jonathan R. , Wu, David , Sohani, Aliyah R. , Vadlamani, Indira U., Ferry, Judith A. , Szigeti, Réka , Tardío, Juan C. , Granados, Rosario , Dertinger, Susanne, Offner, Felix, Pircher, Andreas , Hosry, Jeff , Miranda, Roberto N. , Horna, Pedro , Di Napoli, Arianna , Hunt, Kelly K. , Doǧan, Ahmet , Parkash, Vinita , Piña‐Oviedo, Sergio , Zhang, Da , Hunt, John, Vadlamani, Indira, Morgan, Elizabeth A. , Young, Ken H. , Medeiros, L Jeffrey , Bhagat, Govind , Miranda, Roberto N

Mayo Clinic

American Journal of Surgical Pathology | November 29, 2017 | Volume: 42 | Issue: 3 | Pages: 293-305

10.1097/pas.0000000000000985 | PMID 29194092 Get It

Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a rare T-cell lymphoma that arises around breast implants. Most patients manifest with periprosthetic effusion, whereas a subset of patients develops a tumor mass or lymph node involvement (LNI). The aim of this study is to describe the pathologic features of lymph nodes from patients with BI-ALCL and assess the prognostic impact of LNI. Clinical findings and histopathologic features of lymph nodes were assessed in 70 patients with BI-ALCL. LNI was defined by the histologic demonstration of ALCL in lymph nodes. Fourteen (20%) patients with BI-ALCL had LNI, all lymph nodes involved were regional, the most frequent were axillary (93%). The pattern of involvement was sinusoidal in 13 (92.9%) cases, often associated with perifollicular, interfollicular, and diffuse patterns. Two cases had Hodgkin-like patterns. The 5-year overall survival was 75% for patients with LNI and 97.9% for patients without LNI at presentation (P=0.003). Six of 49 (12.2%) of patients with tumor confined by the capsule had LNI, compared with LNI in 8/21 (38%) patients with tumor beyond the capsule. Most patients with LNI achieved complete remission after various therapeutic approaches. Two of 14 (14.3%) patients with LNI died of disease compared with 0/56 (0%) patients without LNI. Twenty percent of patients with BI-ALCL had LNI by lymphoma, most often in a sinusoidal pattern. We conclude that BI-ALCL beyond capsule is associated with a higher risk of LNI. Involvement of lymph nodes was associated with decreased overall survival. Misdiagnosis as Hodgkin lymphoma is a pitfall.